An international, randomized, placebo‐controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY‐DLB)

An international, randomized, placebo‐controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY‐DLB)

Abstract Introduction A phase 2b clinical trial, HEADWAY‐DLB, was performed to assess treatment with intepirdine, a serotonin receptor antagonist, in patients with dementia with Lewy bodies (DLB). Methods HEADWAY‐DLB was a multinational, double‐blind, randomized, placebo‐controlled study. Two hundre...

Full description

Bibliographic Details
Main Authors: Frederick M. Lang, Daniel Y. Kwon, Dag Aarsland, Brad Boeve, Babak Tousi, Mark Harnett, Yi Mo, Marwan Noel Sabbagh
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
5‐HT6
clinical trial
dementia with Lewy bodies
intepirdine
phase 2b
Online Access:https://doi.org/10.1002/trc2.12171

Similar Items

Similar Items